+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
ID07884955

Randomized Study Comparing Inclisiran Plus Spironolactone Versus Statin Plus Spironolactone in Primary Aldosteronism

Led by Third Military Medical University · Updated on 2026-10-21

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Primary aldosteronism is a common cause of resistant high blood pressure. Researchers are comparing two treatment approaches to see how they affect aldosterone levels and other health markers in patients with this condition. The trial focuses on the use of inclisiran, a cholesterol-lowering drug, combined with amlodipine besylate, versus traditional statin therapy, aiming to find better management options for primary aldosteronism. Participants are randomly assigned to receive either inclisiran by injection plus oral amlodipine besylate and spironolactone, or oral statins combined with amlodipine besylate and spironolactone. The study compares these two regimens over a 24-week period to evaluate differences in aldosterone levels and other clinical measures. During the study, participants undergo regular monitoring of plasma aldosterone, blood pressure, plasma renin concentration, urinary aldosterone, serum potassium, lipid levels, and glucose. These assessments help researchers understand the treatments effects. The trial lasts 24 weeks after randomization, with careful follow-up to track changes in these important health parameters.

CONDITIONS

Brief Title

Comparing Inclisiran Versus Statin for Primary Aldosteronism

Research Team

L

Liyuan Yuan

Z

Zhiming Zhu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here